Pegasta 6Mg Injection

Pegasta 6mg Injection is a prescription supportive-care medicine containing pegfilgrastim, designed to help cancer patients reduce the risk of infection during chemotherapy. This long-acting injection is widely used in oncology to support patients’ immune systems and maintain safe chemotherapy schedules under professional medical supervision.

The active ingredient, pegfilgrastim, stimulates the bone marrow to produce neutrophils, the white blood cells that help the body fight infections. By boosting neutrophil counts, Pegasta helps prevent febrile neutropenia and supports overall treatment continuity, improving patient safety during chemotherapy cycles.

Pegasta 6 mg Injection ensures reliable potency, safety, and effectiveness. This prescription-only oncology product must be administered by qualified healthcare professionals, with regular monitoring to achieve optimal supportive-care outcomes for patients undergoing cancer treatment.

Product Features

• Supportive-care oncology injection
• Contains Pegfilgrastim 6 mg
• Helps reduce chemotherapy-induced neutropenia
• Long-acting granulocyte colony-stimulating factor (G-CSF)
• Sterile injectable formulation
• Reduces the risk of infection during chemotherapy
• Manufactured under strict pharmaceutical quality standards
• Prescription-required medication

How It Helps

• Stimulates bone marrow to produce neutrophils, supporting immune defense
• Helps reduce chemotherapy-induced neutropenia and related infections
• Supports safe continuation of chemotherapy treatment
• Long-acting formulation ensures sustained neutrophil protection